Catalyst Event
Amgen Inc (AMGN) · Other
From Akros U.S. Large Cap 500 Index (AUL500)
3/23/2026, 12:00:00 AM
Amgen announced on March 23, 2026, that its Phase 3 ROCKET-Outpost study for rocatinlimab, a treatment for atopic dermatitis, has been completed. The study evaluated the self-administration of the drug.
Korean Translation
2026년 3월 23일, 아토피 피부염 치료제 로카틴리맙(rocatinlimab)의 자가 투여를 평가하는 3상 ROCKET-Outpost 연구가 완료되었음을 발표함.
Related Recent Events
Micron Technology Inc. (MU) · Earnings Release
Micron's fiscal third-quarter 2026 earnings release is scheduled for June 24, 2026, scheduled. High importance is estimated as earnings releases for major semiconductor companies typically result in price impacts exceeding 10%.
6/24/2026, 12:00:00 AM
Apple Inc (AAPL) · Other
Apple's annual Worldwide Developers Conference (WWDC) is scheduled to begin on June 8, 2026, to unveil iOS 27 and major AI advancements; these updates are estimated to have a >5% price impact scheduled
6/8/2026, 12:00:00 AM
Hewlett Packard Enterprise Co (HPE) · Earnings Release
Hewlett Packard Enterprise Co is expected to announce its Q2 2026 earnings results on June 2, 2026 scheduled.
6/2/2026, 12:00:00 AM
NetApp Inc (NTAP) · Earnings Release
Q4 2026 earnings release including analyst EPS forecasts of $2.25-$2.27 forecasted, scheduled. Medium importance estimated as quarterly earnings are major catalysts for this stock.
5/28/2026, 12:00:00 AM
Palo Alto Networks Inc (PANW) · Earnings Release
Palo Alto Networks' next earnings release for Q3 2026 is scheduled for May 19, 2026. Low importance as it is a routine scheduled announcement with no results yet, scheduled.
5/19/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Next earnings release for Q1 2026 is scheduled for 2026-05-14, with analysts forecasting an EPS of -$0.04. A neutral impact is expected as the market typically waits for actual results, so the release is forecasted and scheduled.
5/14/2026, 12:00:00 AM